BiotechTube
Aculys Pharma

Aculys Pharma

Tokyo, Japan· Est.

A Japanese neuroscience biotech addressing drug lag by licensing and commercializing overseas-approved treatments for epilepsy and sleep disorders.

aculys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Estimated funding: $140M

AI Company Overview

A Japanese neuroscience biotech addressing drug lag by licensing and commercializing overseas-approved treatments for epilepsy and sleep disorders.

NeurosciencePsychiatry

Technology Platform

The company utilizes a 'bridge' business model rather than a technology platform, focusing on licensing clinical-stage or approved drugs from overseas partners for development and commercialization in Japan.

Opportunities

Significant opportunity to address the large and growing drug lag in Japanese neuroscience, with potential to expand its pipeline by licensing additional late-stage or approved CNS assets from global biopharma companies.

Risk Factors

Commercial execution risk for its first product launch; dependency on successful NDA submissions and approvals for pitolisant; and potential competition from other companies targeting the same niche.

Competitive Landscape

Aculys faces competition from large pharma companies with CNS portfolios and other Japanese biotechs, but differentiates through its exclusive focus on bridging the neuroscience drug lag and its streamlined development model for in-licensed assets.

More companies in Japan →